A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Title:A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer

Volume: 14 Issue: 3

Author(s): Juana Rodriguez*, Gregorio Castaneda, Isabel Lizcano and Jose C. Villa

Affiliation:

• Department of Analytical Chemistry and Food Technology, University of Castilla La Mancha. Ciudad Real,Spain

Keywords: Abiraterone acetate, abiraterone, HPLC, fluorescence detection, biological fluids, prostate cancer.

Abstract: Background: An accurate HPLC-fluorescence method for the simultaneous determination of abiraterone acetate (prodrug) and abiraterone (drug) employed in the treatment of prostate cancer, in urine and serum samples of men treated with this prodrug has been proposed.

Methods: The developed HPLC-FLD procedure permits the quantification of ABR and AA minimizing laborious and complicated sample preparation procedures. The selectivity of the fluorescence detector avoids the presence of endogenous and exogenous interfering compounds and has enough sensibility for this determination.

Results: The method was applied for the analysis of human urines samples of five men and serum samples of two men under treatment of prostate cancer. The excretion urinary in a patient was done during 24 hours. The maximum abiraterone concentration for this patient was 27 ng/mL.

Conclusion: This method shows the advantage of being suitable for the analysis of urine and serum samples of patients with prostate cancer who received daily doses of Zytiga.

Cite this article as:

Rodriguez Juana*, Castaneda Gregorio, Lizcano Isabel and Villa C. Jose , A Rapid, Direct and Validated HPLC- Fluorescence Method for the Quantification of Abiraterone and Abiraterone Acetate in Urine and Serum Samples from Patients with Castration- Resistant Prostate Cancer, Current Pharmaceutical Analysis 2018; 14 (3) . https://dx.doi.org/10.2174/1573412913666170213152002